Advertisement NBER selects Medidata Solutions to assess clinical trial costs - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

NBER selects Medidata Solutions to assess clinical trial costs

National Bureau of Economic Research (NBER) research project has selected Medidata Solutions' Grants Manager and CRO Contractor for evaluating the major causes of increasing drug development costs.

The NBER researchers are expected to use the data from Medidata’s proprietary clinical trial cost databases PICAS and CROCAS, accessed through Medidata Grants Manager and Medidata CRO Contractor, for building and testing the feasibility and accuracy of cost indices to track clinical development costs.

Medidata Solutions CEO Tarek Sherif said they are excited that the data available through Medidata Grants Manager and CRO Contractor will enable the NBER-affiliated researchers to better understand cost factors in clinical trials, helping manage the economic impact of drug research and development on the economy at large.